Philadelphia
Gold rises on renewed US stimulus hope, dollar falls
Spot gold rose 0.3 percent to $1,910.56 an ounce at 3:37pm, New York time, after falling as much as 0.5 percent. Gold rose on renewed optimism for a preelection aid package in the U.S., while the dollar fell to a one-week low. House Speaker Nancy Pelosi said a bill for a compromise stimulus package is being written as she awaits a key phone call with Treasury Secretary Steven Mnuchin. Senate Majority Leader Mitch McConnell said his chamber would take up a comprehensive coronavirus package if an accord is struck. The Bloomberg Dollar Spot Index headed for the third straight decline. Pelosi said in a Bloomberg Television interview that while there are areas where more work is required to get a compromise, she was pleased with the Trump administration’s latest position on coronavirus testing ...
Floating Movie Theaters Coming to New York, Los Angeles, Chicago, and More US Cities
Parisians were treated to a floating movie theater adventure this past weekend. Apparently it went swimmingly because now a different company, Beyond Cinema, is bringing a similar idea to America. Starting this September, Beyond Cinema will launch 12 to 24 mini boats — each of which can hold upwards of eight people — in US cities. Movies will be projected on a large screen outdoors near the water, and patrons can pay to watch the film in comfort from one of the floating vessels. The Australian entertainment and event company originally found success with their “boat-in” events back during pre-COVID times. Once the current pandemic set in, though, they decided to modify the event to uphold safety measures while still capitalizing on this creative way to keep movie lovers entertained. O...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
